Surge in third-party funding sparks wave in FTSE shareholder lawsuits Lawsuit A surge in the availability of third-party funding has triggered a wave of speculative FTSE shareholder lawsuits as investors seek to cash in on claims of wrongdoing. Over the last year, multiple blue-chip names, including gambling giant Entain, smoking tycoon British American Tobacco (BAT), and fast fashion retailer Boohoo, have been summoned before the High [...]
IGI Announces the Launch of Cipher, A Specialty Treaty Reinsurance Platform Focused on Cyber Business Wire International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC), the international specialty insurance and reinsurance group, today announced the launch of Bermuda-based Cipher Underwriting Ltd. (“Cipher”), a specialty treaty reinsurance managing general agent (MGA) established to provide dedicated cyber treaty underwriting expertise and solutions on a global basis. The commencement of Cipher’s operations [...]
Litigation funders need certainty to keep Britain’s class action regime fair Opinion Litigation funding is an exceptionally risky business, which current delays and uncertainty over new rules is worsening, writes Leslie Perrin.
Law firm at centre of BHP mammoth lawsuit sued by its own funder August 18, 2026 City law firm Pogust Goodhead is facing an £84m lawsuit from its own funder over a dispute related to its high-profile case: the record-breaking group action against mining giant BHP. The firm, formerly known as PGMBM, recently secured a major victory in one of the largest legal actions ever heard in the English courts. Last [...]
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering August 12, 2026 Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United [...]
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares August 10, 2026 Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares (“ADSs”), each representing three ordinary shares of £0.05 each in the capital of the Company, in the [...]
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET
Thames Water faces fresh threat to survival after pensions regulation breach August 8, 2026 Thames Water is facing a fresh threat to its survival after breaching pensions regulations, opening up the possibility of a costly probe. The Reading-based business, which could run out of cash as soon as December, missed a statutory deadline at the end of June to value its company pension scheme and is now facing a [...]
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets August 7, 2026 2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 [...]
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights August 5, 2026 Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360’s potential to establish a new standard of care in TRD COMP360 has a highly differentiated clinical profile and is expected to be a blockbuster opportunity, if approved Rolling NDA submission and initial review underway and final submission expected to be completed in Q4 Commercial launch expected in first half of 2027 COMP360 expected to fit seamlessly into current treatment infrastructure Late-stage PTSD trial underway Strong cash position of $433 million at the end of second quarter, providing cash well beyond launch and into 2028 Compass management will host a conference call on August 5 at 8:00 am ET